News
Post Doctoral Scientist post available at Boehringer - Research Beyond Borders working with the UK Cystic Fibrosis Gene Therapy Consortium
8 years ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
8 years ago Flutterby Fundraisers to Sponsor Consortium Scientist
8 years ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
9 years ago Gene Therapy Funding Update
9 years ago Consortium Student Live Facebook Interview from ASGCT
9 years ago
8 years ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
8 years ago Flutterby Fundraisers to Sponsor Consortium Scientist
8 years ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
9 years ago Gene Therapy Funding Update
9 years ago Consortium Student Live Facebook Interview from ASGCT
9 years ago
MHRA Approval for Multi-Dose Clinical Trial
Tuesday, June 12th 2012
Last week the MHRA (Medicines and Healthcare Products Regulatory Agency) granted the final approval necessary for the main body of work in our planned clinical trial to begin.
With everything now in place, the first patient visits in London and Edinburgh will take place over the next week.
Due to the number of patients enrolled and the 12 visits/patient over 12 months, the trial has a staggered start and finish and will run until sometime in the first half of 2014.
Dr Uta Griesenbach talks about our Lentiviral Research Programme. (2011): Brief introduction to our Lentivirus work, filmed around the time of our two wins at the 2011 Medical Futures Innovation Awards. More...
